StockData
Kura Oncology, Inc. logo

Kura Oncology, Inc. (KURA) stock

KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)

Close on Nov 18, 2026Market cap $652.97MP/E –Yield –

Kura Oncology total assets

Total assets on the balance sheet at the end of each period.

Kura Oncology's total assets was $566.50M at Sep 30, 2026. For fiscal 2025 it was $738.36M, down 2.9% from the year before. Over ten years it grew 23.8% a year on average. The highest annual figure on record is $760.16M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$738.36M-2.9%
FY2024Dec 31, 2024$760.16M+69.3%
FY2023Dec 31, 2023$448.94M-1.6%
FY2022Dec 31, 2022$456.31M-14.6%
FY2021Dec 31, 2021$534.05M-17.5%
FY2020Dec 31, 2020$647.21M+167.5%
FY2019Dec 31, 2019$241.97M+32.7%
FY2018Dec 31, 2018$182.38M+90.3%
FY2017Dec 31, 2017$95.85M+37.3%
FY2016Dec 31, 2016$69.82M-20.0%
FY2015Dec 31, 2015$87.26M+6232.3%
FY2014Dec 31, 2014$1.38M+15096.3%
FY2013Dec 31, 2013$9.07K+9.2%
FY2012Dec 31, 2012$8.30K–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$566.50M-12.8%
Q2 FY2026Jun 30, 2026$587.79M-13.9%
Q1 FY2026Mar 31, 2026$652.55M-12.3%
Q4 FY2025Dec 31, 2025$738.36M-2.9%
Q3 FY2025Sep 30, 2025$649.38M+35.6%
Q2 FY2025Jun 30, 2025$682.43M+32.5%
Q1 FY2025Mar 31, 2025$743.76M+34.3%
Q4 FY2024Dec 31, 2024$760.16M+69.3%
Q3 FY2024Sep 30, 2024$478.84M+1.1%
Q2 FY2024Jun 30, 2024$515.12M+4.1%
Q1 FY2024Mar 31, 2024$553.91M+30.0%
Q4 FY2023Dec 31, 2023$448.94M-1.6%
Q3 FY2023Sep 30, 2023$473.77M+5.8%
Q2 FY2023Jun 30, 2023$494.74M+4.9%
Q1 FY2023Mar 31, 2023$425.98M-14.6%
Q4 FY2022Dec 31, 2022$456.31M-14.6%
Q3 FY2022Sep 30, 2022$447.99M-20.2%
Q2 FY2022Jun 30, 2022$471.43M-19.4%
Q1 FY2022Mar 31, 2022$498.59M-19.6%
Q4 FY2021Dec 31, 2021$534.05M-17.5%
Q3 FY2021Sep 30, 2021$561.14M+65.3%
Q2 FY2021Jun 30, 2021$584.89M+65.7%
Q1 FY2021Mar 31, 2021$620.26M+173.9%
Q4 FY2020Dec 31, 2020$647.21M+167.5%
Q3 FY2020Sep 30, 2020$339.57M+33.4%
Q2 FY2020Jun 30, 2020$353.00M+32.9%
Q1 FY2020Mar 31, 2020$226.46M+33.5%
Q4 FY2019Dec 31, 2019$241.97M+32.7%
Q3 FY2019Sep 30, 2019$254.60M+33.0%
Q2 FY2019Jun 30, 2019$265.69M+105.0%
Q1 FY2019Mar 31, 2019$169.62M+19.9%
Q4 FY2018Dec 31, 2018$182.38M+90.3%
Q3 FY2018Sep 30, 2018$191.50M+85.7%
Q2 FY2018Jun 30, 2018$129.63M+132.1%
Q1 FY2018Mar 31, 2018$141.46M+128.5%
Q4 FY2017Dec 31, 2017$95.85M+37.3%
Q3 FY2017Sep 30, 2017$103.12M–
Q2 FY2017Jun 30, 2017$55.85M–
Q1 FY2017Mar 31, 2017$61.92M–
Q4 FY2016Dec 31, 2016$69.82M–

More Kura Oncology figures

See a number that looks wrong?